Biogen has appointed Michel Vounatsos as its executive vice-president and chief commercial officer.
Mr Vounatsos most recently served as president of Merck Sharp and Dohme’s primary care and customer centricity units, as part of a 20-year career with the company.
He will be responsible for overseeing the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of its product portfolio and the development of its commercial infrastructure.
Dr George Scangos, chief executive officer of Biogen, said: “Michel will play a critical role in driving our near-term growth while helping prepare our organisation to support our increasingly robust and diverse pipeline.”
Mr Vounatsos will take up his new post on April 18th.